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Abstract: A new type of coronavirus (2019-nCoV) is rapidly spreading worldwide and causes pneumonia, respiratory distress,
thromboembolic events, and death. Chest computed tomography (CT) plays an essential role in the diagnosis of viral pneumonia,
monitoring disease progression, determination of disease severity, and evaluating therapeutic efficacy. Chest CT can show important
clues of 2019-nCoV disease (also known as COVID-19) in patients with an appropriate clinic. Prompt diagnosis of COVID-19 is
essential to prevent disease transmission and provides close clinical observation of patients with clinically severe disease. Therefore,
radiologists and clinicians should be familiar with the CT imaging findings of COVID-19 pneumonia. Herein, we aimed to review
the imaging findings of COVID-19 pneumonia and examine the critical points to be considered for imaging in cases with COVID-19
suspicion.
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1. Introduction
Since December 2019, a novel bat-origin coronavirus (2019nCoV), also known as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), capable of infecting humans
has been identified, and the disease caused by this virus
was officially named as COVID-19 by the World Health
Organization [1]. Until April 27 2020, there were 2,804,796
confirmed cases with COVID-19 and 193,710 COVID-19
related deaths [2]. COVID-19 is a rapidly spreading viral
disease and can cause serious health problems, especially
pneumonia, necrotizing encephalopathy, systemic
and pulmonary thromboembolism, acute respiratory
distress syndrome (ARDS), respiratory failure, systemic
inflammatory response, and sepsis [1,3–5]. Therefore,
professional consensus, guidelines, and criteria have
been published continuously to facilitate the diagnosis,
management, follow-up, and isolation of patients [6–8].
Although the reverse transcription-polymerase chain
reaction (RT-PCR) test is the gold standard for the diagnosis
of COVID-19, chest x-ray and computed tomography
(CT) have an essential role in the diagnosis, follow-up, and
staging of COVID-19 pneumonia [3,5,9]. Chest CT may
reveal parenchymal involvement in COVID-19 patients,
including the areas of ground-glass opacities (GGO),
interlobular septal thickening, prominent intralobular
lines, and consolidation areas [9–14]. Moreover, especially

in the early phases of the COVID-19 infection or in the
presence of disease with a low viral load, the RT-PCR test
may be negative, but CT may reveal significant findings
[14,15]. However, in patients with COVID-19, especially
in the early stage of the disease, chest CT can be found
entirely normal, and normal CT does not rule out the
disease. Moreover, chest radiography can be used in
COVID-19 patients, but its diagnostic value is very limited.
Therefore, it is recommended to use chest radiography
in the assessment of lung involvement in paediatric and
pregnant patients or in the follow-up of hospitalized
patients, especially in case of severe or critical illness [16].
With growing global concerns about COVID-19
pandemic, radiologists and clinicians should be familiar
with the imaging findings of COVID-19 pneumonia.
Herein, we aimed to review the imaging findings of
COVID-19 pneumonia and examine the critical points
to be considered for imaging in cases with COVID-19
suspicion.
2. Usual imaging findings
The reported prevalence of the common CT findings is
shown in Table 1.
2.1. Ground glass opacity
Ground glass opacity (GGO) is an increase in lung
density without obscuring vascular margins in the
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Study
Origin
5 (100%)
36 (72%)
12 (57%)
41 (34%)
73 (91%)
39 (77%)
54 (85.7%)
18 (86%)
15 (71%)
65 (60%)
65 (72%)
87 (86.1%)
25 (40.3%)
30 (73%)
46 (90.2%)
409 (46%)
81 (97.6%)
42 (100%)
200 (91%)
11 (100.0)
53 (65%)
69 (74.2%)
124 (83%)
82 (35%)
107 (89%)
36 (50%)
30 (27.3%)
45 (80.4%)
47 (100%)
50 (75%)

GGO

-

2 (40%)
6 (29%)
50 (41%)
30 (59%)
44 (41%)
65 (64.4%)
25 (61%)
28 (54.9)
141 (64%)
7 (63.6)
119 (50%)
59 (82%)
50 (45.4%)
43 (76.8%

GGO with
consolidation

GGO; ground-glass opacity, PVE; pulmonary vascular enlargement.

Number of
patients

Publication

Table 1. The reported prevalence of the usual computed tomography findings.

0
2 (2%)
50 (63%)
28 (55%)
12 (19.0%)
13 (62%)
19 (91%)
6 (6%)
12 (13%)
44 (43.6%)
21 (33.9%)
15 (37%)
3 (5.9)
447 (50%)
53 (63.9%)
23 (55%)
150 (69%)
6 (54.5)
14 (17%)
56 (60.2%)
6 (3%)
62 (52%)
16 (22%)
30 (27.3%)
12 (21.4%)
30 (64%)
8 (12%)

Consolidation
4 (19%)
6 (5%)
23 (29%)
38 (75%)
17 (81%)
43 (40%)
11 (12%)
39 (62.9%)
33 (80%)
36 (70.6)
30 (36.1%)
11 (5%)
8 (10%)
34 (36.6%)
53 (35%)
30 (25%)
25 (44.6%)
42 (89%)
28 (42%)

41 (80%)
52 (48%)
7 (8%)
45 (72.6%)
22 (54%)
35 (68.6)
81 (54.4%)
14 (33%)
30 (14%)
8 (72.7)
38 (47%)
54 (36%)
24 (20%)
48 (67%)
41(73.2%)
36 (77%)
-

16 (13%)
9 (11%)
53 (52.5%)
20 (32.2%)
26 (17.4%)
19 (22.9%)
19 (9%)
3 (27.3)
9 (11%)
44 (47.3%)
12 (8%)
14 (12%)
19 (28%)

Crazy paving Air
Airway
pattern
bronchogram changes
86 (80%)
72 (71.3%)
28 (45.2%)
42 (82.4)
129 (59%)
83 (89.2%)
33 (46%)
-

PVE
8 (7%)
16 (20%)
11 (22%)
11 (17.5%)
55 (61%)
49 (48.5%)
35 (56.5%)
10 (19.6)
79 (53%)
8 (1%)
4 (4.8%)/ 54 (65.1%
15 (36%)
123 (56%)/ 111 (51%)
9 (81.8)
3 (4%)
15 (16.1)
22 (18%)
44 (61%)
30 (53.6%)
-

Reticular and/
or linear pattern
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lung parenchyma because of partial filling of air spaces,
interstitial lung disease, increased capillary blood volume,
partial alveolar collapse, or a combination of these, the
common factor being the partial displacement of air [17].
Ground glass opacities with a peripheral and multi-lobar
distribution is a common finding in COVID-19 patients,
and GGO is usually more prominent in lower-middle
lobes and posterior lung areas (Figures 1a and 1b). The
reported prevalence of GGO varies between 46% and
100%, and GGO has usually seen in the early phases of the
disease and/or mild pulmonary infection [9–11,13,14,18–
43]. As the disease stage and severity increase, usually
consolidation and/or interstitial thickening (crazy paving
pattern) begins to appear within the GGO areas. Besides,
while GGO or consolidation are healing, it can be seen as
a GGO containing fibrotic band or atelectasis in the lung
[31].
2.2. Consolidation
Pulmonary consolidation is defined as an increase in
lung density with obscuring vascular margins in the
lung parenchyma due to the complete replacement of air
spaces (alveolus and alveolar sacs) by fluid, pus, blood,
or cells [17]. Peripheral, segmental, or sub-segmental
consolidation areas with the multi-lobar distribution
are usually seen in cases with COVID-19 pneumonia,
especially in older patients and patients with severe or
critical disease (Figure 2) [11,14–16,31,39]. Consolidation
areas are usually seen in mixed patterns with GGO, and
the new emergence of consolidation areas in the followup imaging of COVID-19 patients was considered as an
indicator of progressive disease [11]. Besides, consolidative
lesions have been reported in COVID-19 patients with
a longer time interval between onset of symptoms and

chest CT scan, or patients over 50 years of age [31,39].
The prevalence of thromboembolic events in patients
with COVID-19 has been shown to increase compared
to the healthy population. Therefore, when CT shows
peripherally located, triangular-shaped consolidation
areas, pulmonary thromboembolism, and infarction
(Hampton hump) should be considered in the differential
diagnosis [44,45].
2.3. Crazy paving pattern
The crazy paving pattern indicates a ground-glass opacity
(GGO) with superimposed interlobular septal thickening
and prominent intralobular lines [14,17]. Crazy paving
pattern opacities are not uncommon in COVID-19 patients,
and the reported prevalence of crazy paving pattern
varies between 5% and 89% [9–11,13,14,18–43] (Figures
1a and 1b) (Table 1). Crazy paving pattern may indicate
interstitial inflammation and alveolar damage in patients
with COVID-19, which had been previously reported in
patients with Middle East Respiratory Syndrome (MERS)
and the Severe Acute Respiratory Syndrome (SARS) [46].
In the follow-up, the increase in the density of GGO and the
emergence of opacities with the crazy paving pattern was
demonstrated in the early stage of COVID-19 pneumonia.
Moreover, the progression of the crazy paving pattern to
consolidation and the emergence of pleural effusion have
been reported in the late stage of COVID-19 pneumonia
[8,19,31].
2.4. Air bronchogram and airway changes
Air bronchogram is the appearance of air-filled and low
attenuated bronchi on a background of the high attenuated
opaque lung, and the air bronchogram has almost always
been caused by airspace pathology [17]. Air bronchogram
sign has been frequently reported in cases with COVID-19

Figure 1. a) A 48-year-old man with COVID-19 presented with cough, fever, myalgia, and malaise for 3 days. Axial chest CT
image shows multifocal, peripheral-peribronchovascular ground-glass opacities (red frames). b) The magnified image of the
right lower lobe shows ground-glass opacity superimposed with interlobular septal thickening and prominent intralobular lines
(red arrowheads), which indicates a crazy-paving pattern.
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Figure 2. A 66-year-old symptomatic man with COVID-19 pneumonia. Axial CT image at the carina level shows peripheral
ill-defined consolidation areas in the both middle-lower lung zones with subpleural involvement (red arrowheads). Note the “air
bronchogram sign” within the consolidation areas.

pneumonia (Figures 3a and 3b). Song et al. [18] have been
reported that 80% (n = 41/51) of patients with COVID-19
pneumonia had air bronchograms. Besides, COVID-19
patients may have airway changes such as endobronchial
mucus plugging, bronchiectasis, bronchioloectasis, and
bronchial wall thickening [9–11,13,14,18–43] (Table 1).
Moreover, the prevalence of bronchial wall thickening in
COVID-19 patients with severe-critical clinical features
has been shown to be significantly higher than in patients
with mild-common clinical features [14,41].
2.5. Pulmonary vascular enlargement
Pulmonary vascular enlargement (PVE), also known as
pulmonary vascular widening, is defined as the widening
of the subsegmental pulmonary vessel (pulmonary arteries
and veins) with a diameter of more than 3 mm around
and/or inside the opacity on CT (Figures 4a and 4b)
[24,25,27,32,35,39]. Although the pathophysiology of PVE

is not fully understood, PVE plays a potential diagnostic
role for COVID-19. Bai and colleagues [32] had compared
the CT findings in patients with COVID-19 pneumonia
and non-COVID-19 pneumonia, and they found that
the PVE was significantly associated with COVID-19 (P
< 0.001, 59% vs. 22%). Moreover, PVE was reported in
45.2% to 89.2% of COVID-19 patients [24,25,27,32,35,39]
(Table 1). PVE can be attributed to the vascular wall
inflammatory infiltration [24,32,35].
2.6. Reticular pattern and linear opacification
The reticular pattern is the pathological process of the
pulmonary interstitium and characterized by interlobular
septal thickening and prominent intralobular lines
[17]. The reticular pattern is usually seen in COVID-19
patients with pneumonia and reticulation may increase in
patients with longer disease course [8,19,31]. The reported
prevalence of reticular pattern and linear opacification
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Figure 3. A 33-year-old woman with COVID-19 presented with cough, fever, and pleuritic chest pain for 2 days. Axial chest CT
image shows a focal consolidation with air bronchogram sign in the right lower lobe (a, red arrows). The sagittal reconstructed
CT image of the right lower lobe shows air bronchogram sign inside the consolidation (b, red arrow).

Figure 4. A 46-year-old woman with COVID-19. Axial chest CT image shows peripheral and peribronchovascular distributed
focal ground-glass opacities in both lungs, and focal vascular enlargement is seen inside the ground-glass opacity in the right
lower lobe (a, red frame). The magnified image of the red frame shows vascular enlargement inside the ground-glass opacity
(b, arrows).

is very variable in the literature and has been reported
between 1% and 81% [13,14,18,19,23–41]. Moreover,
subpleural curvilinear lines and fibrous stripes have
been reported in COVID-19 patients (Figures 5a and 5b)
[14,18–43], and both may represent the replacement of
cellular components by fibrosis [14,19]. It has been shown
that cured patients with COVID-19 pneumonia may have
persistent reticular opacities on CT [31].
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2.7. Pulmonary embolism
Life-threatening thromboembolic events are increasingly
identified in COVID-19 patients [44,45,47]. Recently,
Grillet and colleagues [44] reported the prevalence
of pulmonary embolism (PE) as 23% (n = 23/100) in
COVID-19 patients with severe clinical features, and
they reported that COVID-19 patients with PE, had a
higher requirement for mechanical ventilation than those

UFUK and SAVAŞ / Turk J Med Sci

Figure 5. a) A 66-year-old symptomatic man with COVID-19. Axial CT image shows subpleural fibrous stripes with groundglass opacities in both lower lobes (red frames). b) A 53-year-old man with COVID-19. Axial CT image shows subpleural
curvilinear lines, interlobular septal thickening, and fibrous stripes with ground-glass opacities in both lower lobes (red frames).

without PE. Moreover, Leonard-Lorant et al. [47] reported
that 22 of 106 patients (30%) with COVID-19 had acute
pulmonary thromboembolism. Elevated D-dimer levels
have been frequently reported in COVID-19 cases,
especially in COVID-19 patients with PE [5,45,47].
Current guidelines recommend performing unenhanced
chest CT for COVID-19 suspected patients with risk
factors and/or severe-critical clinical findings. However,
thromboembolic events associated with COVID-19
infection are not uncommon. Besides, especially
those treated in the intensive care unit and patients in
mechanical ventilation therapy are in the high-risk group
for deep venous thrombosis and PE [44,45]. Therefore,
pulmonary CT angiography is essential for evaluating lung
parenchyma and vascular complications for COVID-19
cases with severe and/or critical clinical features and
high D-dimer levels (Figures 6a, 6b, and 6c). Recently,
the British Thoracic Imaging Association has suggested
that if pulmonary CT angiography (CTA) is required in a
potential COVID-19 patient, prior to CTA, an unenhanced
chest CT should be performed because mosaic attenuation
in CTA can be confused with GGO [48].
3. Unusual imaging findings
The reported prevalence of the unusual CT findings is
shown in Table 2.
3.1. Pleural thickening and effusion
Pleural pathologies such as pleural effusion and focal
pleural thickening have been rarely reported in cases with
COVID-19, and pleural pathologies are usually seen in
the later stages of the disease [21,31,39]. The presence of

pleural effusion is thought to be a sign of poor prognosis
in COVID-19 pneumonia, and the prevalence of pleural
effusion in COVID-19 patients has been reported to range
from 0% to 20% [11,13,14,18–43] (Table 2). Besides, the
pleural effusion and thickening might be associated with
dense pleural inflammation in patients with COVID-19
(Figures 6a, 6b, 6c, 7a, 7b) [24].
3.2. Air bubble sign
The air bubble sign has been defined as a small aircontaining space that may be a pathological enlargement
of bronchioles inside the opacity [25,28]. Air bubble sign
is named in the literature under different names (cystic air
space, round cystic changes, air-containing space, sievehole sign, and vacuolar sign). Although its pathophysiology
is unclear, it may be related to the pathological expansion
of alveolar sacs or bronchioles or the absorption process of
consolidation, and the reported prevalence of air bubble
sign in patients with COVID-19 pneumonia ranges from
8.1% to 54.8% (Figure 8) [25,28,33, 34, 35,39] (Table 2).
3.3. Nodules
A nodule refers to opacity in the lung parenchyma, less
than or equal to 3 cm in diameter [17]. Shi and colleagues
[34] reported that lung nodules were detected in 6% of
patients with COVID-19 pneumonia. Similarly, Li and
colleagues [30] reported that pulmonary nodules with or
without visible halo sign were detected in 7.2% of patients
with COVID-19 pneumonia (Figure 9). The halo sign
indicates GGO surrounding a pulmonary nodule or mass
and usually seen in patients with invasive fungal infections,
hypervascular pulmonary metastases, and organizing
pneumonia [17]. Although it is reported in the literature

669

UFUK and SAVAŞ / Turk J Med Sci

Figure 6. A 40-year-old female patient was presented with complaints of fever that had been ongoing for 5 days, and newly
emerged severe dyspnoea. The patient’s D-dimer level was found to be very high and contrast-enhanced pulmonary CT
angiography was obtained. a) Axial CT image at the level of the origin of the middle lobe bronchus with mediastinum window
settings shows bilateral diffuse pulmonary embolism (red arrows), bilateral mild pleural effusion, and subpleural triangularshaped opacity with a reverse halo sign in the left lung compatible with pulmonary infarction (red frame). b, c) Axial CT images
of the same patient with lung window settings show multiple subpleural consolidation and ground-glass opacity areas (red
frames). The nasopharyngeal swab test of the patient was positive for 2019-nCoV.

that tree-in-bud pattern nodules can be seen in patients
with COVID-19 [24,28, 33,35], superimposed bacterial
infections or aspiration should be considered first when
these nodules are detected.
3.4. Reversed halo sign
The reversed halo sign (RHS) indicates a central GGO
surrounded by denser ring-like (crescentic shape)
consolidation and also known as the Atoll sign [17].
Although RHS is usually seen in patients with cryptogenic
organized pneumonia (COP), it has been reported in
several cases with COVID-19 [13,20,27,32,35]. While
Bernheim et al. [13] reported that the reversed halo sign
was detected in 2 of 121 patients (1.7%) with COVID-19
pneumonia, Wang et al. [35] reported the prevalence of
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reversed halo sign as 15.1% (14 of 93 patients) (Table 2)
(Figure 10).
3.5. Spider web sign
The “spider web sign” was defined by Wu and colleagues
[14], and they described it as an angular or triangularshaped peripheral GGO with interstitial thickening like
a spider web in a corner, but its pathophysiology has not
been clearly revealed. They reported that the reversed
halo sign was detected in 20 of 80 patients (25%) with
COVID-19 pneumonia [14]. Moreover, Li et al. [30]
detected the spider web sign in 21 of 83 (25.3%) patients
with COVID-19 pneumonia. Apart from these 2 studies,
there are no other studies in the literature describing or
investigating the “spider web sign”. Therefore, this finding
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Table 2. The reported prevalence of the unusual computed tomography findings.
Publication

Number of
patients

Study
Origin

Pleural thickening Air bubble
Nodules
and/or effusion
sign

Reversed
halo sign

Spider
web sign

LAP

Pericardial
effusion

Chung et al. [11]

21

China

0 (0%)

-

0 (0%)

-

-

0 (0%)

-

Bernheim et al. [13]

121

U.S.A.

1 (0.8%)

-

0 (0%)

2 (1.7%)

-

0 (0%)

-

Wu et al. [14]

80

China

5 (6%)

-

-

-

20 (25%)

3 (4%)

4 (5%)

Song et al. [18]

51

China

4 (8%)

-

-

-

-

3 (6%)

3 (6%)

Pan et al. [19]

63

China

-

-

8 (12.7%)

-

-

-

-

Ng et al. [20]

21

China

0 (0%)

-

1 (4.8%)

2 (9.6%)

-

0 (0%)

0 (0%)

Pan et al. [21]

21

China

-

-

-

-

-

0 (0%)

-

Han et al. [22]

108

China

0 (0%)

-

-

-

-

0 (0%)

0 (0%)

Xu et al. [23]

90

China

4 (4%)

-

-

-

-

1 (1%)

1 (1%)

Zhao et al. [24]

101

China

14 (13.9%)

-

23 (22.8%) -

-

1 (1%)

-

Zhou et al. [25]

62

China

6 (9.7%)

34 (54.8%) -

-

-

0 (0%)

-

Xu et al. [26]

41

China

2 (7.1%)

-

-

-

-

1(3.6%)

-

Li et al. [27]

51

China

1 (2.0 %)

-

11 (21.6%) 2 (3.9 %)

-

0 (0%)

-

Yang et al. [28]

149

China

10 (6.7%)

12 (8.1%)

3 (2%)

-

-

7 (4.7%) -

Ai et al. [29]

888

China

-

-

24 (3%)

-

-

-

Li et al. [30]

83

China

7 (8.4%)

-

6 (7.2%)

-

21 (25.3%) 7 (8.4%) 4 (4.8%)

Xiong et al. [31]

42

China

5 (12%)

-

-

-

-

12 (29%) 0 (0%)

Bai et al. [32]

219

China

32 (15%)

-

70 (32%)

11 (5%)

-

6 (3%)

-

Cheng et al. [33]

11

China

0 (0%)

1 (9.1)

3 (27.3)

-

-

0 (0%)

-

Shi et al. [34]

81

China

4 (5%)

8 (10%)

5 (6%)

-

-

5 (6%)

-

Wang et al. [35]

93

China

8 (8.6%)

12 (12.9%) 17 (18.3%) 14 (15.1%) -

6 (6.5%) -

Fan et al. [36]

150

China

6 (4%)

-

18 (12%)

-

-

2 (1.3%) -

Colombi et al. [37]

236

Italy

47 (20%)

-

-

-

-

57 (24%) -

Zhang et al. [38]

120

China

9 (8%)

-

65 (54%)

-

-

5 (4%)

-

Zhu et al. [39]

72

China

3 (6.8)

36 (50%)

-

-

-

-

-

Wang et al. [40]

110

China

1 (0.9%)

-

-

-

-

-

-

Li et al. [41]

56

China

5 (8.9%)

-

0 (0%)

-

-

0 (0%)

-

Guan et al. [42]

47

China

0 (0%)

-

1 (2.1%)

-

-

0 (0%)

-

Liu et al. [43]

67

China

3 (4.5%)

-

-

-

-

-

-

-

LAP; lymphadenopathy.

needs to be investigated in patients with non-COVID-19
pneumonia and COVID-19 pneumonia.
3.6. Lymphadenopathy
Mediastinal lymphadenopathy has been infrequently
reported in COVID-19 patients, and lymphadenopathy
has been shown as a risk factor for severe and progressive
COVID-19 pneumonia [14,31,37]. In the literature, the
frequency of mediastinal lymphadenopathy has been
reported between 0% and 29% in patients with COVID-19
[11,13,14,18–38]. Lymphadenopathy is a rare finding in
viral pneumonia, and the detection of pleural effusion,

lung nodules with a tree-in-bud pattern, and ill-defined
micronodules may suggest bacterial superinfection [31–
34].
3.7. Pericardial effusion
Pericardial effusion has been rarely reported in COVID-19
patients, which may indicate the occurrence of myocardial
and/or pericardial inflammation [14,18,23,30]. Li et al.
[30] have reported that COVID-19 patients with severe
and critical diseases showed a higher frequency of
pericardial effusion than noncritical patients. Recently, Xu
et al. [23] found the pericardial effusion in 1 of 90 (1.1%)
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Figure 7. A 56-year-old man with COVID-19. Axial chest CT image with lung window settings shows bilateral focal groundglass opacities in both lungs (a, red frame). Chest CT image with mediastinum window settings shows focal pleural thickening
in the left lower lobe, near the focal ground-glass opacity (b, arrowheads).

Figure 8. A 75-year-old symptomatic man with COVID-19. Axial chest CT image shows mixed opacity (ground-glass opacity
with consolidation) area in the right middle lobe (red frame), and that includes cystic air space (air bubble, red arrow).
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Figure 9. A 36-year-old woman presented with complaints of cough and fever for 2 days. Axial chest CT image shows a nodule
with halo sign in the right upper lobe (red arrow). The nasopharyngeal swab test of the patient was positive for 2019-nCoV, and
the nodule disappeared at follow-up.

patients with COVID-19 pneumonia. However, elderly
patients, and especially those with additional heart failure,
may have pericardial effusion independent of COVID-19.
4. Structured CT reporting for assessment of COVID-19
Although chest CT findings in COVID-19 patients can
partially overlap with other diseases, especially other types
of viral infections, COVID-19 may have characteristic
CT features that are less common in other diseases
[32]. Various recommendations have been published to
standardize the structured CT reporting for the suspected
COVID-19. The first of these is the Radiological Society of
North America (RSNA) expert consensus statement, which
suggests a standardized reporting and a classification of
imaging features for COVID-19 pneumonia (i.e. negative
for typical appearance, vague appearance, atypical
appearance, and pneumonia) [49]. Salehi and colleagues
[50] have defined a new classification by analysing 37
published studies that examined the diagnostic chest CT
findings of COVID-19 patients. There are 5 categories in
this classification: COVID-RADS 0; normal CT findings,
COVID-RADS 1; atypical CT findings (inconsistent with
COVID-19), COVID-RADS 2A; fairly typical findings,
COVID-RADS 2B; combination of atypical findings

with typical/fairly typical findings, and COVID-RADS 3;
typical CT findings [50] (Table 3). However, the groups in
this classification are based on the results obtained from
a systematic review, and clinical success and applicability
of this classification are unknown. Recently, the Dutch
Radiological Society defined a new classification (CORADS) for pulmonary involvement in cases presenting
with moderate to severe symptoms of COVID-19 [51]. In
this standardized assessment (CO-RADS), a substantial
agreement was found among 8 observers (Fleiss’ kappa of
0.47, 95% CI 0.45–0.49) and the discriminatory power of
the CO-RADS for diagnosing COVID-19 was high (with
an area under the curve value of 0.91, 95% CI 0.85–0.97).
Therefore, the authors stated that CO-RADS is very
suitable for use in clinical practice [51] (Table 4).
5. The severity of pulmonary involvement on CT
The visual (semiquantitative) evaluation of disease
severity on chest CT can reflect the clinical classification
(mild, common, severe, or critical disease) and prognosis
of patients with COVID-19 pneumonia [11,30,41].
Therefore, the staging of lung involvement has been
defined in COVID-19 patients. In these staging methods,
the percentage of each lung lobe involvement is assessed,
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Figure 10. A 58-year-old man with COVID-19. Axial chest CT image with lung window settings shows bilateral multifocal
ground-glass opacities in both lungs. The ground-glass opacity in the left lower lobe surrounded by denser ring-like (crescentic
shape) consolidation, which is compatible with a reversed halo sign (arrowheads).

and the portion of the total lung involvement is calculated
semiquantitatively (visually). For example, Chung et al.
[11] and Li et al. [41] used the same scoring as follows:
none (0%); a score of 0, minimal (1%–25%); a score of 1,
mild (26%–50%); a score of 2, moderate (51%–75%); a
score of 3, and severe (76%– 100%); a score of 4. An overall
lung involvement score was reached by summing the 5
lobe scores (0–20). Besides, quantitative CT assessment
methods and artificial intelligence applications can be
successfully applied in the diagnosis of COVID-19 and in
the evaluation of disease severity [37,52,53].
6. Radiation concern
Exposure to medical radiation is a concern in patients
with suspected or diagnosed COVID-19 pneumonia,
especially in infants, children, young adults, and
pregnant patients. Therefore, it is necessary to prevent
or reduce radiation exposure [6,7,20,54]. First, it should
be distinguished appropriately in which patients need
imaging and in which patient imaging is not needed. In
cases with COVID-19 suspicion, imaging methods should
be avoided if clinical follow-up and management will not
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change. In a multinational recommendation that is newly
defined and widely used by Fleischner Society, imaging is
not recommended for cases with suspected of COVID-19
without risk factors (such as diabetes, older age, chronic
obstructive pulmonary disease) and mild clinical findings.
Moreover, imaging methods are indicated in a COVID-19
patient whose respiratory condition has worsened [6].
Second, chest CT should be obtained as low as possible
radiation dose in cases with CT indication. Dangis et al.
[54] showed that chest CT with low-dose settings would
provide the diagnosis of COVID-19 pneumonia with
similar accuracy as standard-dose chest CT.
7. Contamination of radiology units
Radiography machines and CT scanners are frequently
used in patients with suspected COVID-19 during the
pandemic. Therefore, vital precautions should be provided
for COVID-19 in radiology units [6,55]. First, ensuring
the health of radiology workers is essential for the best
care of patients. For this reason, staff working in radiology
units should use necessary personal protective equipment
according to their contact with the patient. Besides, all
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Table 3. The proposed coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) [50].
CT findings

Description

Normal chest CT
Atypical findings

- Pleural effusion

(Inconsistent with COVID-19)

- Cavity

COVID-RADS
grade

Level of
suspicion

0

Low

1

Low

2A

Moderate

2B

Moderate

3

High

- Pulmonary nodule(s)
- Nodular pattern
- Lymphadenopathy
- Peribronchovascular distribution
- Halo sign
- Tree-in-bud sign
- Bronchiectasis
- Airway secretions
- Pulmonary emphysema
- Pulmonary fibrosis
- Isolated pleural thickening
- Pneumothorax
- Pericardial effusion
- Single GGO (early)
- Consolidation without GGO (late/complicated)
- Focal pleural thickening
Fairly typical findings

- Vascular enlargement
- Air bronchogram
- Bronchial wall thickening
- White lung stage (late/complicated)
- Parenchymal fibrotic bands (late/remission)

Combination of atypical findings
with typical/fairly typical findings
- Multifocal GGO
- GGO with superimposed consolidation
- Consolidation predominant pattern
Typical findings

(late/complicated)
- Linear opacities (late/complicated)
- Crazy paving pattern (late/complicated)
- Melted sugar sign (late/remission)

GGO, ground glass opacity.

patients with a suspicion for COVID-19 who presented
to the radiology unit should use a standard surgical mask.
Second, contamination of radiography machines and CT
scanners are a major concern. Therefore, it is necessary
to use a dedicated radiography machine and CT device
in patients with suspicion for COVID-19 to reduce the
risk of disease transmission. Also, these dedicated devices

should never be used in patients without suspicion for
COVID-19. Third, to reduce the risk of contamination,
the CT scanners and radiography devices and rooms must
be deeply cleaned and disinfected according to standard
protocols after each exam. If patient masking is available,
active (mechanically) air exchange procedures are not
required [6,55]. After each imaging procedure, the room
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Table 4. The proposed CO-RADS categories and the corresponding level of suspicion for pulmonary involvement in COVID-19 [51].
Level of suspicion for
pulmonary involvement
of COVID-19

Summary

CO-RADS 0

Not interpretable

Scan technically insufficient for assigning a score

CO-RADS 1

Very low

Normal or noninfectious

CO-RADS 2

Low

Typical for other infection but not COVID-19

CO-RADS 3

Equivocal/unsure

Features compatible with COVID-19, but with also other diseases

CO-RADS 4

High

Suspicious for COVID-19

CO-RADS 5

Very high

Typical for COVID-19

CO-RADS 6

Proven

RT-PCR positive for SARS-CoV-2

downtime for the decontamination of room and devices is
approximately 30 min.
8. Conclusion
In conclusion, early diagnosis of COVID-19 is essential to
prevent transmission and provide close clinical observation
of the patients. While the gold standard for the diagnosis of
COVID-19 is RT-PCR, CT should be obtained in a limited
population (in COVID-19 patients who have worsening
respiratory symptoms, in patients with moderate-severe
clinical features of COVID-19, in medical triage of
COVID-19 suspected cases with moderate-severe clinical
features, and a high pretest probability of COVID-19 in the
lack of personal protective equipment or availability of RT-

PCR test) due to radiation concern. Although bilateral and
peripheral GGO without or with superimposed interstitial
thickening (crazy-paving pattern), and/or consolidation
with the multi-lobar distribution is the common CT
features in COVID-19, chest CT features can vary among
patients. Moreover, chest CT is not just a diagnostic or
screening method in cases with suspected COVID-19. In
patients with COVID-19, chest CT is especially crucial
in determining the severity of pneumonia, which has a
prognostic impact [11,37,41].
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